Fractionated-dose radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody (epratuzumab).: Interim results.

被引：0
|
作者：
Chatal, JF
Harousseau, JL
Truemper, LH
Meller, J
Pfreundschuh, M
Kirsch, CM
Naumann, R
Kropp, J
Wegener, WA
Ding, C
Horak, ID
Goldenberg, DM
机构：
[1] Inst Biol, INSERM, Res Unit 4, Nantes, France
[2] Ctr Hosp Univ, Serv Hematol, Nantes, France
[3] Univ Gottingen, D-3400 Gottingen, Germany
[4] Univ Saarland, Sch Med, Hamburg, Germany
[5] Univ Hosp Dresden, Dresden, Germany
[6] Immunomed Inc, Morris Plains, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1482
引用
收藏
页码：408A / 408A
页数：1
相关论文
共 50 条
  • [21] Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Tsai, DE
    Maillard, I
    Schuster, SJ
    Nasta, SD
    Porter, DL
    Klumpp, TR
    Goldenberg, DM
    Luger, SM
    Alavi, A
    Sharkey, RM
    Hartzell, KB
    Stadtmauer, EA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 56 - 59
  • [22] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Postema, EJ
    Oyen, WJG
    Boerman, OC
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 853 - 853
  • [23] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    Wiseman, GA
    White, CA
    Witzig, TE
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Grillo-López, AJ
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3281S - 3286S
  • [24] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Wagner, HN
    Wiseman, GA
    Marcus, CS
    Nabi, HA
    Nagle, CE
    Fink-Bennett, DM
    Lamonica, DM
    Conti, PS
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (02) : 267 - 272
  • [25] Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)
    Leonard, JP
    Link, BK
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 81 - 86
  • [26] Epratuzumab - Humanized anti-CD22 MAb non-Hodgkin's lymphoma therapy treatment of systemic lupus erythematosus treatment of Sjogren's syndrome
    Davies, SL
    Martin, L
    DRUGS OF THE FUTURE, 2005, 30 (07) : 683 - 687
  • [27] Zevalin™ (IDEC-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL):: Interim results.
    Gordon, LI
    White, CA
    Witzig, TE
    Flinn, I
    Czuczman, M
    Wiseman, GA
    Spies, S
    Olejnik, T
    Zhang, C
    Grillo-Lopez, AJ
    Lurie, RH
    BLOOD, 1999, 94 (10) : 91A - 91A
  • [28] Radioimmunotherapy (RIT) of non-Hodgkin's lymphoma (NHL) with I-131 anti-CD20 monoclonal antibody (Bexxar™).: Preliminary results
    Antonescu, C
    Buchegger, F
    Kosinski, M
    Ketterer, N
    Kovacsovics, T
    Helg, C
    Delaloye, AB
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 980 - 980
  • [29] I-131-LL2 (anti-CD22) radioimmunotherapy (RIT) of refractory non-Hodgkin's lymphoma (NHL): Results of a repetitive dosing trial.
    Vose, J
    Colcher, D
    Bierman, P
    Leichner, P
    Akabani, G
    Harrison, K
    Hohenstein, M
    Lesser, S
    Hammershaimb, L
    Goldenberg, DM
    Tempero, M
    Armitage, J
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 211 - 211
  • [30] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90yttrium anti-CD20 monoclonal antibody.
    Wiseman, G
    Witzig, T
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanouilides, C
    Gutheil, J
    Parker, E
    Chinn, P
    Grillo-Lopez, A
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 59 - 59
12345